Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.


Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
06 2020
Historique:
received: 01 04 2020
revised: 04 04 2020
accepted: 04 04 2020
pubmed: 11 4 2020
medline: 24 6 2020
entrez: 11 4 2020
Statut: ppublish

Résumé

Infection caused by SARS-CoV-2 can result in severe respiratory complications and death. Patients with a compromised immune system are expected to be more susceptible to a severe disease course. In this report we suggest that patients with systemic lupus erythematous might be especially prone to severe COVID-19 independent of their immunosuppressed state from lupus treatment. Specifically, we provide evidence in lupus to suggest hypomethylation and overexpression of ACE2, which is located on the X chromosome and encodes a functional receptor for the SARS-CoV-2 spike glycoprotein. Oxidative stress induced by viral infections exacerbates the DNA methylation defect in lupus, possibly resulting in further ACE2 hypomethylation and enhanced viremia. In addition, demethylation of interferon-regulated genes, NFκB, and key cytokine genes in lupus patients might exacerbate the immune response to SARS-CoV-2 and increase the likelihood of cytokine storm. These arguments suggest that inherent epigenetic dysregulation in lupus might facilitate viral entry, viremia, and an excessive immune response to SARS-CoV-2. Further, maintaining disease remission in lupus patients is critical to prevent a vicious cycle of demethylation and increased oxidative stress, which will exacerbate susceptibility to SARS-CoV-2 infection during the current pandemic. Epigenetic control of the ACE2 gene might be a target for prevention and therapy in COVID-19.

Identifiants

pubmed: 32276140
pii: S1521-6616(20)30239-4
doi: 10.1016/j.clim.2020.108410
pmc: PMC7139239
pii:
doi:

Substances chimiques

CD11a Antigen 0
Cytokines 0
Interferon Regulatory Factors 0
NF-kappa B 0
Receptors, KIR 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108410

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI097134
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI110502
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None of the authors has any financial conflict of interest to disclose.

Références

J Immunol. 2007 Oct 15;179(8):5553-63
pubmed: 17911642
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
J Autoimmun. 2018 Jan;86:19-28
pubmed: 29066026
Clin Immunol. 2015 Jan;156(1):19-27
pubmed: 25451162
Arthritis Rheumatol. 2016 Sep;68(9):2200-9
pubmed: 27111767
J Autoimmun. 2014 Nov;54:127-36
pubmed: 25091625
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Front Immunol. 2018 Apr 24;9:875
pubmed: 29740453
Arthritis Rheumatol. 2014 Jun;66(6):1574-82
pubmed: 24577881
J Autoimmun. 2013 Jun;43:78-84
pubmed: 23623029
Nat Rev Rheumatol. 2013 Nov;9(11):674-86
pubmed: 24100461
J Immunol. 2007 Nov 1;179(9):6352-8
pubmed: 17947713
Cell Rep. 2020 Jan 7;30(1):112-123.e4
pubmed: 31914379
Curr Rheumatol Rep. 2017 Jun;19(6):32
pubmed: 28470479
J Autoimmun. 2015 Apr;58:59-66
pubmed: 25638528
J Autoimmun. 2009 Aug;33(1):31-4
pubmed: 19464849
Am J Pathol. 2007 Apr;170(4):1136-47
pubmed: 17392154
Ann Rheum Dis. 2018 May;77(5):736-743
pubmed: 29437559
Lupus Sci Med. 2016 Apr 04;3(1):e000147
pubmed: 27099767
J Immunol. 2008 Dec 15;181(12):8761-6
pubmed: 19050297

Auteurs

Amr H Sawalha (AH)

Division of Rheumatology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; Lupus Center of Excellence, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: asawalha@pitt.edu.

Ming Zhao (M)

Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Patrick Coit (P)

Division of Rheumatology, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA; Graduate Immunology Program, University of Michigan School of Medicine, Ann Arbor, MI, USA.

Qianjin Lu (Q)

Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China; Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH